Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs

An anti-platelet aggregation and drug technology, which can be used in drug combination, drug delivery, blood diseases, etc., and can solve problems such as no NADPH yet

Inactive Publication Date: 2016-01-20
SUZHOU RENBEN PHARMA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the use of NADPH in the treatment of platelet aggregation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs
  • Application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs
  • Application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Preparation of NADPH capsules

[0023] The composition of present embodiment NADPH capsule is:

[0024] NADPH 20g, suspending agent microcrystalline cellulose 60g, preservative tert-butyl-4-hydroxyanisole 0.04g, lubricant magnesium stearate 2g, filler lactose added to 200g.

[0025] Its preparation method comprises the following steps:

[0026] Respectively weigh the NADPH and various pharmaceutical excipients in the above prescription amount, mix them evenly, sieve through a 60-mesh sieve for 3 times, put them into capsule shells, and obtain.

experiment example 1

[0028] Experimental example 1 Effects of exogenous NADPH on adenosine diphosphate (ADP)-induced platelet aggregation in rats in vitro

[0029] (1) Experimental materials

[0030] Adenosine diphosphate (ADP) and thrombin (Thrombin) reagents were purchased from Shenggong Company, and NADPH reagent was purchased from Sigma Company; the source of exogenous NADPH drugs can be obtained through artificial synthesis, semi-synthesis, and biological extraction; adult male SD rats , weighing 270-350g, 20 rats, clean grade, provided by the Experimental Animal Center of Soochow University School of Medicine, [permit number: (Su) SYXK2007-0035].

[0031] The room temperature is 22°C, the humidity is 50-60%, the ventilation is good, artificial day and night (12h / 12h), free to eat and drink.

[0032] Before the experiment, the male rats were acclimatized in the breeding environment for 2 days.

[0033] (2) Experimental plan

[0034] Blood was collected from the abdominal aorta of 20 rats...

experiment example 2

[0042] Experimental example 2 Effects of Exogenous NADPH on Thrombin-Induced Platelet Aggregation in Rats in Vitro

[0043] (1) Experimental materials are the same as Experimental Example 1.

[0044] (2) The experimental scheme is the same as that of Experimental Example 1.

[0045] (3) Experimental method

[0046] 1) Detection of platelet aggregation

[0047] Turn on the platelet aggregation instrument and preheat it for 30 minutes, and use PPP as a blank control to adjust the light transmittance to 100%. Add 0.25mL NADPH samples of different concentrations (30μM, 60μM, 90μM) to PRP, preheat at 37°C for 5min, add a certain amount of Thrombin (2U) after putting it into the detector to induce platelet aggregation, record the graph changes within 4min, and observe the effect of NADPH on Thrombin induction of platelet aggregation.

[0048] 2) Data statistics and analysis

[0049] The data are expressed as mean ± standard error (Mean ± SEM), statistical analysis using one-w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
transmittivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of pharmaceuticals, and particularly relates to an application of NADPH (triphosphopyridine nucleotide) in preparation of antiplatelet aggregation drugs. The research shows that in-vitro delivery of exogenous NADPH inhibits ADP (adenosine diphosphate) induced platelet aggregation of rats in a dose-dependent mode; in-vitro delivery of exogenous NADPH inhibits Thrombin induced platelet aggregation of the rats in a dose-dependent mode; preventive delivery of NADPH in the rats can remarkably inhibit ADP induced platelet aggregation; preventive delivery of NADPH in the rats can remarkably inhibit Thrombin induced platelet aggregation. Therefore, NADPH has the antiplatelet aggregation function and can be taken as a potential antiplatelet aggregation drug.

Description

technical field [0001] The invention belongs to the field of pharmacy, and in particular relates to the application of NADPH in the preparation of anti-platelet aggregation drugs. Background technique [0002] Platelet aggregation is the main step in thrombus formation. In normal circulating blood, platelets are in a resting state. When the vessel wall is damaged, such as the rupture of the atherosclerotic plaque, the subendothelial matrix of the vessel is exposed, the platelet will adhere to the collagen tissue under the endothelium through the combination of its surface membrane glycoprotein (GP) Ib and vorlWillebrand factor (VWF), and at the same time pass through its surface The collagen receptors GPⅠa-Ⅱa and GPVI directly bind to collagen, thereby firmly adhering to the subendothelial collagen tissue. Adhered platelets or platelets subjected to platelet activators (such as collagen, thrombin, etc.) undergo a series of reactions, including arachidonic acid metabolism, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7084A61P7/02
CPCA61K31/7084A61K9/0031A61K9/0053A61K9/0073A61K9/2077A61K9/4808A61P7/02
Inventor 秦正红李梅
Owner SUZHOU RENBEN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com